Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

If you're looking for the most hated stocks on Wall Street, start with this list. All seven companies are worth more than $1 billion but have more than 30% of their available shares held by short ...

Feb 26 (Reuters) - Novavax ⁠raised ⁠its adjusted revenue forecast for ⁠2026 on Thursday, banking on milestone payments from ...

Feb 27 (Reuters) - Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the ‌first single shot to protect people ...

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

The Food and Drug Administration reversed an earlier decision to not review Moderna's flu vaccine and will evaluate the company's modified application for a potential approval, Moderna said on Feb. 18 ...

2024-2025 COVID-19 vaccines reduced hospitalization risk by 40% against JN.1 lineage variants. COVID-19 is still a public threat and health concern. Between 2024 and 2025, an estimated 380,000 to ...

Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...

Ana Santos Rutschman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...

Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing Pfizer (PFE.N), opens new tab access to its technology that boosts immune responses to vaccines ‌for use in up to ...